From the Editor: A Note on the 2020 Redesign
Editor-in-Chief, Dr. Laura Michaelis introduces the 2020 The Hematologist print redesign, including a better layout, more modern look, and clearer signposts within
A Novel Immunotherapy for T-ALL
Drs. Diorio and Teachey discuss the work of researchers that developed two monoclonal antibodies targeting IL-7Rα that proved effective when used separately or in combinati
Insightful critiques and informed commentary of important ongoing clinical trials
Drs. Garcia, Letai, and Kim discuss a trial investigating the use of venetoclax in combination with azacitidine for myelodysplastic syndromes.
Dr. Heidel and Dr. Lane discuss a study of the benefit and risk profile of AOP2014 in low-risk patients with polycythemia vera.
Drs. Friedberg and O'Dwyer discuss a study designed to examine the efficacy of combining nivolumab and BV with a chemotherapy backbone of AVD as initial treatment for older children and adult patients with newly diagnosed stage III or IV classical Hodgkin lymphoma.
Dr. Osunkwo reviews a study that will explore the impact of continuous positive airway pressure on improving rates of vaso-occlusive crisis as well as several biologic parameters of disease severity in individuals with SCD and comorbid obstructive sleep apnea.
Drs. Moll and Nagler discuss the CARAVAGGIO study, an ongoing trial that looks at whether apixaban can be safely and effectively used in patients with cancer and acute deep vein thrombosis or pulmonary embolism.
Dr. DeZern comments on a study in which adult patients with FLT3/ITD acute myeloid leukemia are randomized to receive gilteritinib or placebo after the time of engraftment for a two-year period.
Dr. Fenske and Dr. Kahl discuss a trial enrolling adult patients with mantle cell lymphoma (MCL), who are considered candidates for autologous hematopoietic cell transplantation, to find whether MRD status can be used to personalize therapy in MCL.
Dr. Jacobson reviews a study investigating the safety and efficacy of the anti-CD79b antibody drug conjugate, polatuzumab, in combination with R-CHP versus R-CHOP in previously untreated patients with DLBCL.
Dr. Ding and Dr. Teachey cover a trial that looks at the safety and efficacy of combining the JAK1/JAK2 inhibitor ruxolitinib with post-induction chemotherapy for pediatric patients with Philadelphia chromosome-like B-cell acute lymphoblastic leukemia.
Dr. Linkins discusses the VERDICT Trial which compares reduced doses of apixaban and rivaroxaban with standard-of-care in adult patients with symptomatic proximal deep vein thrombosis or pulmonary embolism and moderate or severe renal insufficiency.
September-October 2019Volume 16, Issue 5
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology